Growth factors and fibrochondrocytes in scaffolds.

J Orthop Res

Department of Bioengineering, Rice University, Houston, Texas 77251, USA.

Published: September 2005

Four growth factors, transforming growth factor-beta1 (TGF-beta1), platelet-derived growth factor-AB (PDGF-AB), insulin-like growth factor I (IGF-I), and basic fibroblastic growth factor (bFGF), were tested at different concentrations for their effects on extracellular matrix (ECM) production in three-dimensional cultures of meniscal fibrochondrocytes. Cells from New Zealand white rabbits were seeded on poly-glycolic acid (PGA) scaffolds and were stimulated with growth factors for three weeks. (3)H-proline and (35)S-sulfate labels were used to measure uptake of collagen and glycosaminoglycan (GAG) components, respectively. Biochemical assays were performed to measure the total collagen, GAG, and DNA present in the scaffolds at the end of the study. TGF-beta1 (10 and 100 ng/ml) stimulated both (3)H-proline and (35)S-sulfate uptake, showing a dose-dependent response for both and a temporal response for (35)S-sulfate uptake. IGF-I (5 ng/ml) and bFGF (25 and 100 ng/ml) showed increases in (3)H-proline uptake by the third week of growth factor addition. PDGF-AB did not show notable increases in uptake. Because TGF-beta1 (10 and 100 ng/ml) had visibly denser scaffolds, as evidenced by gross microscopy, at 100x, and the strongest uptake responses to both (35)S-sulfate and (3)H-proline, it appears to be the most effective growth factor for use in scaffold-based approaches to tissue engineer the knee meniscus.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.orthres.2005.01.019DOI Listing

Publication Analysis

Top Keywords

growth factor
16
growth factors
12
100 ng/ml
12
growth
9
3h-proline 35s-sulfate
8
tgf-beta1 100
8
35s-sulfate uptake
8
uptake
6
factors fibrochondrocytes
4
scaffolds
4

Similar Publications

Exploring the Impact of Systemic Inflammatory Regulators on Rosacea Risk: A Bidirectional Mendelian Randomization Analysis.

Clin Cosmet Investig Dermatol

January 2025

Department of Dermatology, Changshu No. 1 People's Hospital, Changshu Hospital Affiliated to Soochow University, Changshu, Jiangsu, 215500, People's Republic of China.

Objective: Rosacea is a common chronic inflammatory disorder primarily affecting the face. While inflammatory factors are known to play a pivotal role in its pathogenesis, their causal relationship with rosacea remains unclear. This study employed a two-sample bidirectional Mendelian randomization (MR) analysis to investigate the causal links between systemic inflammatory regulators and rosacea.

View Article and Find Full Text PDF

Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities.

J Inflamm Res

January 2025

Precision Medicine Laboratory, School of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, People's Republic of China.

Ovarian cancer (OC) remains one of the most lethal gynecological malignancies, largely due to its late-stage diagnosis and high recurrence rates. Chronic inflammation is a critical driver of OC progression, contributing to immune evasion, tumor growth, and metastasis. Inflammatory cytokines, including IL-6, TNF-α, and IL-8, as well as key signaling pathways such as nuclear factor kappa B (NF-kB) and signal transducer and activator of transcription 3 (STAT3), are upregulated in OC, promoting a tumor-promoting environment.

View Article and Find Full Text PDF

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer, and despite low incidence rates, it remains the sixth leading cause of cancer related deaths worldwide. Immunotherapy, which aims to enhance the immune system's ability to recognize and eliminate cancer cells, has emerged as a promising approach in the battle against PDAC. PARP7, a mono-ADP-ribosyltransferase, is a negative regulator of the type I interferon (IFN-I) pathway and has been reported to reduce anti-tumour immunity.

View Article and Find Full Text PDF

Small molecules targeting activating mutations within the epidermal growth factor receptor (EGFR) are efficacious anticancer agents, particularly in non-small cell lung cancer (NSCLC). Among these, lazertinib, a third-generation tyrosine kinase inhibitor (TKI), has recently gained FDA approval for use in combination with amivantamab, a dual EGFR/MET-targeting monoclonal antibody. This review delves into the discovery and development of lazertinib underscoring the improvements in medicinal chemistry properties, especially in comparison with osimertinib.

View Article and Find Full Text PDF

Blood carries some of the most valuable biomarkers for disease screening as it interacts with various tissues and organs in the body. Human blood serum is a reservoir of high molecular weight fraction (HMWF) and low molecular weight fraction (LMWF) proteins. The LMWF proteins are considered disease marker proteins and are often suppressed by HMWF proteins during analysis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!